Skip to content

Probiotics for Slowing Disability in Relapsing Multiple Sclerosis The PROMISE Trial

Probiotic Supplementation on Disability Progression and Clinico-radiologic Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis (PROMISE): A Randomized, Double-Blind, Placebo-Controlled Trial - PROMISE

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110640
Enrollment
52
Registered
2026-05-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G35- Multiple sclerosis

Interventions

Intervention1: Probiotic supplementation: Participants will be randomised in a 1:1 ratio to receive either an oral probiotic capsule or a matching placebo capsule once daily for a duration of 6 months

Sponsors

JIPMER (Intramural Grant)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults 18-55 years with Relapsing-Remitting MS (RRMS) as per McDonald 2017 criteria 2. EDSS score: 1.0-5.5 3. Stable DMT for at least 3 months 4. At least one documented clinical relapse or MRI activity in the last 2 years

Exclusion criteria

Exclusion criteria: 1. Primary or Secondary Progressive MS 2. Recent probiotic or antibiotic use for 5 days in a week within the past 4 weeks 3. Active infection or gastrointestinal disease, recent GI surgery 4. Pregnancy or breastfeeding 5. Presence of uncontrolled medical conditions such as advanced cardiovascular disease, chronic kidney disease (stage 4 or higher), liver failure, uncontrolled diabetes mellitus, or malignancies

Design outcomes

Primary

MeasureTime frame
Disability progression as measured by the Expanded Disability Status Scale (EDSS)Timepoint: at baseline and 6 months

Secondary

MeasureTime frame
Annualised relapse rateTimepoint: 12 months;Radiologic disease activity as measured by new or enlarging T2 lesions and CEL on MRITimepoint: 12 months;Fatigue using Fatigue Severity Scale (FSS)Timepoint: 6 months;Quality of life using the MS Quality of Life- 54 questionnaireTimepoint: 6 months;Adverse effectsTimepoint: 3 and 6 months;Serum IL-6, IL-10, hsCRP, serum NfLTimepoint: Baseline and 6 months

Countries

India

Contacts

Public ContactSaranya B Gomathy

Jawaharlal Institute of Postgraduate Medical Education and Research

gomathysubramoniam@gmail.com8129606651

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026